secwatch.observer — SEC 8-K summary
======================================

Issuer:     Jasper Therapeutics, Inc. (JSPR)
CIK:        0001788028
Form:       8-K
Filed at:   2023-09-25T23:59:59+00:00
Accession:  0001213900-23-078927
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Jasper Therapeutics appoints Herb Cross as CFO; Jeet Mahal continues as COO
---------------------------------------------------------------------------

- Herb Cross, age 51, appointed CFO and Corporate Secretary effective Sept 22, 2023; prior CFO at Atreca.
- Cross receives $460k base salary, 45% annual bonus target, $100k sign-on bonus.
- Granted option to purchase 550,000 shares at $0.78/share; vests over 4 years (25% cliff at 1 yr, then monthly).
- Jeet Mahal transitions from dual CFO/COO role to solely COO.
- Option is an inducement grant under Nasdaq Listing Rule 5635(c)(4).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1788028/000121390023078927/0001213900-23-078927-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1788028/000121390023078927/ea185698-8k_jasper.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-078927

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer